Which herb is described with indications including warts, cancer (topical use), and constipation, with severe toxicity?

Prepare for the NPLEX II Botanical Medicine Test with comprehensive flashcards and multiple-choice questions. Each question includes hints and detailed explanations to optimize your study session. Ace your NPLEX II with confidence!

Multiple Choice

Which herb is described with indications including warts, cancer (topical use), and constipation, with severe toxicity?

Explanation:
Podophyllum peltatum centers on a potent cytotoxic compound, podophyllotoxin, which is used topically to treat warts (verrucae) and has historical use in topical cancer therapy due to its anti-mitotic action. It is also used internally as a strong laxative to relieve constipation, but this internal use carries a high risk of severe toxicity, including violent GI upset, dehydration, electrolyte disturbances, and potential systemic toxicity. This combination—warts treatment, topical cancer use, and an internal laxative indication with notable danger if misused—fits Podophyllum peltatum most closely. The other herbs lack this specific profile: they do not provide the wart/cancer topical uses or the strong laxative indication with such pronounced toxicity.

Podophyllum peltatum centers on a potent cytotoxic compound, podophyllotoxin, which is used topically to treat warts (verrucae) and has historical use in topical cancer therapy due to its anti-mitotic action. It is also used internally as a strong laxative to relieve constipation, but this internal use carries a high risk of severe toxicity, including violent GI upset, dehydration, electrolyte disturbances, and potential systemic toxicity. This combination—warts treatment, topical cancer use, and an internal laxative indication with notable danger if misused—fits Podophyllum peltatum most closely. The other herbs lack this specific profile: they do not provide the wart/cancer topical uses or the strong laxative indication with such pronounced toxicity.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy